4724-10-1

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 3,5-dihydroxyphenylacetate is used as a reagent for the synthesis of fungal metabolites, specifically cytosporones A, C, J, K, and N. These metabolites have potential applications in the development of new drugs and therapies.
Used in Chemical Synthesis:
Methyl 3,5-dihydroxyphenylacetate is used as a key intermediate in the synthesis of various organic compounds, particularly those with pharmaceutical or biological significance. Its unique structure allows for further functionalization and modification to create novel molecules with potential applications in different industries.

InChI:InChI=1/C9H10O4/c1-13-9(12)4-6-2-7(10)5-8(11)3-6/h2-3,5,10-11H,4H2,1H3

Upstream product

• 13388-75-5 3,5-dimethoxyphenylacetonitrile 
• 6512-32-9 methyl 2-(3,5-dimethoxyphenyl)acetate 
• 4670-10-4 (3,5-dimethoxyphenyl)acetic acid 
• 6512-25-0 dimethyl 2,4-dihydroxy-6-(2-methoxy-2-oxoethyl)benzene-1,3-dicarboxylate 
• 2150-37-0 methyl 3,5-dimethoxybenzoate 
• 6652-32-0 3,5-dimethoxybenzylchloride 
• 705-76-0 3,5-dimethoxybenzyl alcohol 
• 80457-61-0 methanesulfonyl 3,5-dibenzyloxybenzyl alcohol 
• 58604-84-5 (3',5'-dibenzyloxy)phenylacetonitrile 
• 24131-31-5 3,5-dibenzyloxybenzyl alcohol 
• 99-10-5 3,5-Dihydroxybenzoic acid 
• 58605-10-0 methyl 3,5-bis(benzyloxy)benzoate 
• 2150-44-9 1-carbomethoxy-3,5-dihydroxybenzene 
• 186581-53-3 diazomethane 

Downstream Products

• 135388-00-0 methyl 1,3-bis(tert-butyldimethylsilyloxy)phenylacetate 
• 6512-32-9 methyl 2-(3,5-dimethoxyphenyl)acetate 
• 36034-03-4 3,5-dihydroxyphenylacetamide 
• 628330-12-1 methyl (3-benzyloxy-5-methoxyphenyl)acetate 
• 80457-68-7 2-(3,5-bisbenzyloxyphenyl)pent-2-ynoic acid 
• 80457-65-4 ethyl 2-(3,5-bisbenzyloxyphenyl)-2-methoxycarbonylacetate 
• 80457-67-6 ethyl methyl 3,5-bisbenzyloxyphenyl(prop-2-ynyl)malonate 
• 65690-34-8 (+/-)-7-<(3,5-Bis-benzyloxy-phenyl)-acetoxy>-octansaeure-<2-trimethylsilyl-aethylester> 
• 367259-04-9 (3-methoxy-5-hydroxy-phenyl)-acetic acid methyl ester 
• 425638-64-8 [3-(2-Triisopropylsilyloxy-ethoxy)-5-hydroxy-phenyl]-acetic Acid Methyl Ester 
• 329317-36-4 [3,5-bis-(2-nitro-4-trifluoromethanesulfonyl-phenoxy)-phenyl]-acetic acid methyl ester 
• 929094-12-2 (3-ethoxy-5-hydroxy-phenyl)-acetic acid methyl ester 
• 953081-79-3 methyl 2-[3,5-bis(trifluoromethylsulfonyloxy)phenyl]acetate 

Relevant academic research and scientific papers

First total synthesis of medicinally important 3,4,7-trimethoxy-9,10-dihydrophenanthrene-1,5-diol

The first total synthesis was successfully achieved for biologically active 9,10-dihydrophenanthrene-1,5-diol. The key features of our synthetic approach are Perkin condensation, followed by bromination, palladium mediated intramolecular C-C bond coupling, and selective isopropyl ether cleavage. Synthesized compounds were purified and characterized by IR, 1HNMR, 13CNMR and HRMS/LC-MS.

Synthesis method of natural product of E-2,3',4,5'-tetrahydroxy diphenyl ethylene

The invention discloses a synthesis method of a natural product of E-2,3',4,5'-tetrahydroxy diphenyl ethylene. According to the method, 1,3-acetone dicarboxylic acid dimethyl ester is used as a starting raw material; condensation and aromatization reactions are performed to obtain 3,5-dihydroxy-2,4-dicarboxylate methyl phenyl acetate; then, hydrolysis and decarboxylation are performed to obtain 3,5-dyhydroxy phenylacetic acid; the 3,5-dyhydroxy phenylacetic acid and 2,4-dihydroxy benzaldehyde take condensation reaction under the existence of alkali to obtain 3-(3,5-dihydroxy phenyl)-7-hydroxy coumarin; next, open loop decarboxylation reaction is performed under the alkaline condition; the natural product of E-2,3',4,5'-tetrahydroxy diphenyl ethylene is obtained. The method has the advantages that the raw materials are easily obtained; the reaction route is simple and fast; the operation is convenient; the yield is higher.

Syntheses of cytosporones A, C, J, K, and N, metabolites from medicinal fungi

The syntheses of the fungal metabolites cytosporones A, (±)-C, and N are reported. And the syntheses of cytosporones J and K are described for the first time. The preparation of racemic cytosporone J and racemic cytosporone K, natural products containing

A diastereoselective formal synthesis of berkelic acid

A formal synthesis of berkelic acid is reported. The strategy employs the combination of a chiral exocyclic enol ether and an achiral isochromanone to afford the chroman spiroketal core via a base-triggered generation and cycloaddition of an o-quinone met

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.

Preparation and catalytic properties of resin bound binuclear rhodium tetracarboxylate complexes

4-(4'-Polystyryimethyloxy)-3-carboxylatomethyloxy-1-phenylacetate bis- μ-coordinated rhodium(II) diacetate complex, a resin-bound analogue of dirhodium tetraacetate in which two adjacent μ-bridging acetate moleties are covalently linked, serves as an efficient, stable and re-useable immobilised alkene hydrofomylation and hydrogenation catalyst.

Synthesis of 3,5-dihydroxyphenylglycine derivatives and the C-terminal dipeptide of vancomycin

Syntheses of optically active 3,5-DMPG and racemic 3,5-DHPG, the latter suitably protected for incorporation into linear peptides modelled on vancomycin, are described and a synthesis of the optically pure protected C-terminal dipeptide of vancomycin is p

Drugs derived from Cannabinoids. Part 8. The Synthesis of Side-chain Analogues of Δ6a,10a-Tetrahydrocannabinol

The continuation of studies on the synthesis of side-chain analogues of Δ6a,10a-tetrahydrocannabinol as potential therapeutic agents has led to the syntheses of a possible metabolite 1-hydroxy-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-dibenzopyran-3-ylacetic acid (1) and 2-(1-hydroxy-6,6,9-trimethyl-7,8,9,10-tetrahydro-6H-dibenzopyran-3-yl)pent-4-ynoic acid (17c).The Pechmann condensation of ethyl 4-methyl-2-oxocyclohexane-1-carboxylate with methyl 3,5-dihydroxyphenylacetate (11), followed by Grignard reaction, was utilized to produce the pyran (1).The key step in the synthesis of the propargylacetic acid (17c) was propargylation of the malonate (15) under phase-transfer catalysis.